筛选条件 共查询到11条结果
排序方式
BioCon China 2021

期刊: DRUGS OF THE FUTURE, 2021; 46 (7)

BioCon China 2021 was held in Shanghai, China, April 22-23, 2021, focusing on the discovery and design, process development and optimization of biolog......

Engineering Fronts: Medicine and Health Engineering Fronts Collaborators

期刊: DRUGS OF THE FUTURE, 2020; 45 (7)

Engineering science and technology are important driving forces in the development of society, and engineering fronts are important guidelines for the......

Research Fronts 2019: Clinical Medicine and Biological Sciences

期刊: DRUGS OF THE FUTURE, 2020; 45 (4)

The world of scientific research presents a sprawling, ever-changing landscape. The ability to identify where the action is and, in particular, to tra......

Gene therapy in the fight against pediatric blood disorders: sickle cell disease and beta-thalassemia

期刊: DRUGS OF THE FUTURE, 2022; 47 (6)

Pediatric blood disorders represent a category of noncancerous diseases typically affecting infants and children. They negatively impact and impair a ......

JIF:0.139

Erfonrilimab

期刊: DRUGS OF THE FUTURE, 2022; 47 (6)

Immunotherapy is a broad-spectrum antitumor strategy that exerts therapeutic effects on various types of tumors. In recent decades, there has been rap......

JIF:0.139

Dalpiciclib. Cyclin-dependent kinase 4/6 (CDK4/6) inhibitor, Treatment of HR+/HER2-and HER2+advanced breast cancer

期刊: DRUGS OF THE FUTURE, 2022; 47 (12)

Breast cancer represents the highest number of new cases of cancer globally. Approximately 80% of patients diagnosed with breast cancer have hormone r......

JIF:0.139

Paxalisib

期刊: DRUGS OF THE FUTURE, 2022; 47 (1)

Gliomas are the most frequent malignant tumors of the central nervous system, with varied outcomes and an unmet need of highly efficacious treatments.......

JIF:0.139

The Repotrectinib

期刊: DRUGS OF THE FUTURE, 2022; 47 (9)

In the past 2 decades, the understanding of cancer pathogenesis at the molecular level has helped therapy-targeting specific oncogenic drivers to be a......

JIF:0.139

Taletrectinib adipate Dual ROS1 and NTRK inhibitor Treatment of non-small cell lung cancer Treatment of solid tumors

期刊: DRUGS OF THE FUTURE, 2022; 47 (7)

Taletrectinib (DS-6051b, AB-106, IBI-344) is an efficacious and highly selective inhibitor of proto-oncogene tyrosine-protein kinase ROS (ROS1) and ne......

JIF:0.139

GTPase KRAS (G12C mutant) inhibitor Treatment of non-small cell lung cancer Treatment of colorectal cancer

期刊: DRUGS OF THE FUTURE, 2022; 47 (11)

Colorectal cancer (CRC) is one of the cancers with high mor-bidity and mortality worldwide, and its treatment and prog-nosis have undergone tremendous......

JIF:0.139

Eptinezumab Anti-CGRP monoclonal antibody Treatment of migraine

期刊: DRUGS OF THE FUTURE, 2017; 42 (10)

Eptinezumab (ALD-403) is a genetically engineered, humanized, desialylated anti-calcitonin gene-related peptide (CGRP) IgG1 monoclonal antibody that s......

JIF:0.14

共11条页码: 1/1页15条/页